

Markus Hansson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6087777/publications.pdf>

Version: 2024-02-01

73
papers

4,406
citations

236925

25
h-index

106344

65
g-index

75
all docs

75
docs citations

75
times ranked

6043
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. <i>European Journal of Haematology</i> , 2022, 108, 34-44.	2.2	10
2	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. <i>Cancer Reports</i> , 2022, 5, e1614.	1.4	1
3	Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden. <i>Acta Haematologica</i> , 2021, 144, 519-527.	1.4	0
4	Germline variants at SOHLH2 influence multiple myeloma risk. <i>Blood Cancer Journal</i> , 2021, 11, 76.	6.2	6
5	Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	12
6	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53
7	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , 2020, 105, 1650-1659.	3.5	19
8	Genetic predisposition for multiple myeloma. <i>Leukemia</i> , 2020, 34, 697-708.	7.2	25
9	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
10	Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. <i>Blood Advances</i> , 2020, 4, 6298-6309.	5.2	22
11	Search for multiple myeloma risk factors using Mendelian randomization. <i>Blood Advances</i> , 2020, 4, 2172-2179.	5.2	27
12	Autologous haematopoietic stem-cell transplantation versus bortezomib+melphalan+prednisone, with or without bortezomib+lenalidomide+dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e456-e468.	4.6	244
13	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. <i>Blood</i> , 2020, 136, 24-26.	1.4	29
14	Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 45-46.	1.4	7
15	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
16	A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 40-41.	1.4	4
17	Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden. <i>Blood Cancer Journal</i> , 2019, 9, 57.	6.2	2
18	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. <i>Human Genomics</i> , 2019, 13, 37.	2.9	14
20	Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. <i>BMC Rheumatology</i> , 2019, 3, 9.	1.6	13
21	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
22	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	2.8	25
23	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	6.2	40
24	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. <i>Blood</i> , 2019, 134, 601-601.	1.4	5
25	Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark. <i>Blood</i> , 2019, 134, 5030-5030.	1.4	0
26	Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study. <i>Blood</i> , 2019, 134, 5037-5037.	1.4	0
27	Lenalidomide versus lenalidomide+Âdexamethasone prolonged treatment after secondâ€line lenalidomide+Âdexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	2.8	1
28	The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. <i>Nature Communications</i> , 2018, 9, 1649.	12.8	22
29	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	12.8	86
30	A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia. <i>Npj Precision Oncology</i> , 2018, 2, 18.	5.4	14
31	Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2058-2062.	7.2	3
32	Bone marrow eosinophils in plasma cell disorders. <i>Experimental Hematology</i> , 2018, 66, 27-31.e5.	0.4	3
33	Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial. <i>Blood</i> , 2018, 132, 800-800.	1.4	6
34	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	7.2	259
35	Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. <i>Blood Cancer Journal</i> , 2017, 7, e573-e573.	6.2	12
36	Identification of sequence variants influencing immunoglobulin levels. <i>Nature Genetics</i> , 2017, 49, 1182-1191.	21.4	90

#	ARTICLE	IF	CITATIONS
37	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	2.2	21
38	NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2017, 102, 459-466.	3.3	21
39	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	3.5	48
40	Direct evidence for a polygenic etiology in familial multiple myeloma. <i>Blood Advances</i> , 2017, 1, 619-623.	5.2	15
41	A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0171205.	2.5	39
42	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
43	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	1.4	102
44	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
45	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	12.8	146
46	Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis. <i>Arthritis Research and Therapy</i> , 2016, 18, 92.	3.5	16
47	Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. <i>Experimental Hematology</i> , 2016, 44, 342-351.e5.	0.4	4
48	Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. <i>Acta Oncologica</i> , 2016, 55, 554-560.	1.8	14
49	Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. <i>Journal of Clinical Oncology</i> , 2016, 34, 8039-8039.	1.6	2
50	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	1.4	0
51	Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 55-61.	3.5	43
52	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2730-2736.	7.0	41
53	Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. <i>Cancer Cell</i> , 2015, 27, 473-488.	16.8	108
54	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. <i>Nature Communications</i> , 2015, 6, 7213.	12.8	101

#	ARTICLE	IF	CITATIONS
55	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	27.0	948
56	Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (lCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). <i>Blood</i> , 2015, 126, 26-26.	1.4	16
57	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. <i>Blood</i> , 2015, 126, 3047-3047.	1.4	1
58	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4225-4225.	1.4	3
59	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , 2015, 126, 727-727.	1.4	32
60	Genetic and epigenetic characterization of hypodiploid acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 42793-42802.	1.8	25
61	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. <i>Leukemia</i> , 2014, 28, 1573-1585.	7.2	108
62	Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG). <i>Blood</i> , 2014, 124, 179-179.	1.4	6
63	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014, 124, 4755-4755.	1.4	10
64	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8513-8513.	1.6	19
65	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8625-TPS8625.	1.6	2
66	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4770-4770.	1.4	1
67	The Epitope Targeted by Apoptosis-Inducing ICAM-1 Antibody B11 Is Highly Expressed in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 4897-4897.	1.4	4
68	Targeted Therapy by Using Tissue Specific Promoter and Granules as Storage Compartments for Therapeutic Proteins in Hematopoietic Cells.. <i>Blood</i> , 2009, 114, 4508-4508.	1.4	0
69	Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers. <i>European Journal of Haematology</i> , 2007, 79, 159-165.	2.2	12
70	Reactivation of Latent Epstein Barr Virus Infection Induces Remission of Splenic Lymphoma with Villous Lymphocytes. <i>International Journal of Hematology</i> , 2005, 81, 413-416.	1.6	1
71	Activation of cytotoxic lymphocytes by interferon- γ : role of oxygen radical-producing mononuclear phagocytes. <i>Journal of Leukocyte Biology</i> , 2004, 76, 1207-1213.	3.3	21
72	Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. <i>Blood</i> , 2000, 96, 1961-1968.	1.4	148

#	ARTICLE	IF	CITATIONS
73	Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. <i>Blood</i> , 2000, 96, 1961-8.	1.4	68